Sensitization of Epithelial Cancer Cells with Human Monoclonal Antibodies; Targeting the Transferrin Receptor to Overcome Resistance to Anti-Cancer Agents; Chemo-Immunosensitization of Resistant B-NHL as a Result of Rituximab (anti-CD20 mAb)-Mediated Inhibition of Cell Survival Signaling Pathways; Agents that Regulate DR5 and Sensitivity to TRAIL; Proteasome Inhibition: Potential for Sensitization of Immune Effector Mechanisms in Cancer; Angiogenesis Inhibitors as Enabling Agents for the Chemotherapeutic Treatment of Metastatic Disease
Summary
Cancer chemotherapy can be traced back to the 1940a (TM)s and since then the world has witnessed the discovery and the important application of several new drugs. The successes of combination chemotherapy suggested that all cancers can be treated provided that the correct combination of drugs at the correct doses and correct intervals are established. However, with time, tumor cells develop mechanisms of resistance to apoptosis and no longer respond to the majority of cytotoxic therapies. Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy, edited by Benjamin Bonavida, reviews novel a
